Lung squamous cell carcinoma (LUSC) showed HuR-associated gemcitabine/taxane sensitization (R = 0.38-0.44, p < 0.01) alongside potential mTOR inhibitor (AZD8055) resistance (R = -0.29, p < 0.05). This evidence concerns the gene MTOR and squamous cell lung carcinoma.